Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06426628 · ClinicalTrials.gov registry record

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

A clinical trial of Lung Cancer and Pulmonary Nodule, Solitary, sponsored by Veracyte.

Recruiting
Registry status
2,400
Enrollment target
20
Study locations

NCT06426628 is a study of Lung Cancer and Pulmonary Nodule, Solitary that is actively recruiting participants, run by Veracyte. The registered enrollment target is 2,400 participants, above the 930-participant average among 409 other Lung Cancer trials with a reported enrollment target (158% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06426628, a study of Lung Cancer and Pulmonary Nodule, Solitary, is actively recruiting participants, sponsored by Veracyte.

RECRUITING
Registry status
2,400 participants
Enrollment target
20
Study locations

Study Summary

The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: * Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign? * Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is cancer? Participants will be randomly assigned to either a group where the test result is provided to the physician (test arm) or to a group where the test result is not provided (control arm). Researchers will compare management of participants in the two groups.

Conditions Studied

Lung Cancer Pulmonary Nodule, Solitary

Study Locations (20)

Florida

  • Bay Pines VA HCS - Bay Pines
  • North Florida/South Georgia Veterans Health System - Gainesville
  • Bruce W. Carter Miami VA Medical Center - Miami
  • Orlando VA Healthcare System - Orlando

Connecticut

  • Trinity Health Of New England - Hartford
  • The Stamford Health/The Stamford Hospital - Stamford

Illinois

  • Northwestern University - Chicago
  • OSF Saint Francis Medical Center - Peoria

Kentucky

  • Lexington VA Health Care System - Lexington
  • Robley Rex VA Medical Center - Louisville

Missouri

  • Saint Lukes Hospital - Kansas City
  • Mercy Hospital - Springfield

New York

  • University of Rochester Medical Center - Rochester
  • Good Samaritan Cancer Center - West Islip

Kansas

  • University of Kansas Medical Center - Kansas City

Louisiana

  • Southeast Louisiana Veterans Health Care System - New Orleans

Trial Details

FieldValue
Enrollment Target 2,400 participants
Start Date 2022-07-18
Est. Completion 2027-03-31

Sponsor

Veracyte

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06426628

The ClinicalTrials.gov registry entry for NCT06426628 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 930-participant average among 409 other Lung Cancer trials with a reported enrollment target (158% higher). The listed sponsor is Veracyte, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT06426628 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Connecticut, Illinois.

Frequently Asked Questions

What is clinical trial NCT06426628 about?

NCT06426628 is a clinical study titled "Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier". The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: * Does the use of the Percepta Nasal swab test reduce the number of invasive proce...

What is the current status of trial NCT06426628?

This trial is currently recruiting. The enrollment target is 2,400 participants. The study started on 2022-07-18. Estimated completion is 2027-03-31.

What conditions does trial NCT06426628 study?

This clinical trial studies the following conditions: Lung Cancer, Pulmonary Nodule, Solitary.

Who is sponsoring clinical trial NCT06426628?

This trial is sponsored by Veracyte, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06426628 being conducted?

This trial has 20 study locations across Connecticut, Florida, Illinois, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Pulmonary Nodule, Solitary

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.